Clinical trials: Ulcer, Gastric
Duodenal Ulcer
Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer
The purpose of this study is to determine the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with duodenal ulcer.
- Trial name
- NCT01452724
- Testing
- TAK-438, Lansoprazole
- Where
- 64 sites in Japan
- Volunteers
- 372 people
- Sponsor
- Takeda
Aspirin-Associated Gastric Ulcers
Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers
This study uses an open-label design and will be conducted in approximately 40 sites in the United States. Approximately 400 subjects will be enrolled in the study to ensure that approximately 300 subjects will have 6 months…
- Trial name
- NCT00995410
- Testing
- PA32540
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- POZEN
Reflux Esophagitis
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.
- Trial name
- NCT01860482
- Testing
- Newrabell® Tablet 10mg
- Where
- 2 sites in South Korea
- Volunteers
- 39 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract
Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers
Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence (bioequivalence) of drug Antareit 800 mg chewable tablets and drug Riopan 800 mg chewable tablets in healthy volunteers.
- Conditions
- Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract, Symptomatic Treatment of Gastric and Duodenal Ulcers
- Trial name
- NCT06552624
- Testing
- Magaldrate
- Where
- 3 sites in Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Gastroduodenal Ulcer
BE Study of Gaster®D Tab 20mg (Manufacturer Changed)
An Open-Label, Randomized, Two-sequence, Two-period, Fasting Condition, Single Oral Dose, Cross-over Study of Bioequivalence of "Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)" and "Gaster®D Tab 20mg (Famotidine) (Unchanged…
- Trial name
- NCT04123899
- Testing
- IGAD→GSTD, GSTD→IGAD
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Islet Cell Adenoma, Neoplasm Metastasis
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors.
- Conditions
- Islet Cell Adenoma, Neoplasm Metastasis, Zollinger Ellison Syndrome
- Trial name
- NCT00001165
- Testing
- combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HELICOBACTER PYLORI INFECTIONS, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe
Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD).
- Trial name
- HP-MICI (NCT07292454)
- Testing
- Biopsies
- Where
- Guadeloupe
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Reflux Esophagitis
Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
The purpose of this survey is to evaluate the safety and effectiveness of long-term administration of vonoprazan tablets when used as maintenance therapy for reflux esophagitis in routine clinical settings.
- Trial name
- NCT03214081
- Testing
- Vonoprazan
- Where
- Japan
- Volunteers
- 1,237 people
- Sponsor
- Takeda
Marginal Ulcer
OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers
The goal of this clinical trial is to identify the most effective way to take acid-blocking medications to treat stomach ulcers in patients who have undergone gastric bypass surgery.
- Trial name
- OPEN-IT (NCT05799105)
- Testing
- Omeprazole 40 milligrams
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Stephen Firkins
Duodenal Ulcer
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)
Patients with endoscopically diagnosed active duodenal ulcer disease were enrolled in a randomized, double-blind, parallel and dose-ranging trial.
- Trial name
- NCT00953381
- Testing
- 5 mg ilaprazole, 10 mg ilaprazole, 20 mg ilaprazole
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Peripheral Vascular Access in Pediatric Patients, Peptic Ulcer
The Effect of Vascular Imaging Devices on Success Rates of Peripheral Vascular Access in Pediatric Patients
The study was designed as a prospective, observational study. Pediatric patients under 18 years of age scheduled for peripheral vascular access placement during day-case surgery or non-operating room anesthesia (NORA) will be…
- Conditions
- Peripheral Vascular Access in Pediatric Patients, Peptic Ulcer, Cataract, Crohn's Disease
- Trial name
- NCT07315711
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Sibel Seçkin Pehlivan
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00255164
- Testing
- Dexlansoprazole MR
- Where
- 96 sites in United States
- Volunteers
- 451 people
- Sponsor
- Takeda
Peptic Ulcer
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
Whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.
- Trial name
- NCT02551744
- Testing
- histamine-2 receptor antagonist group, proton pump inhibitor group
- Where
- Taiwan
- Volunteers
- 101 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Non-variceal Upper Gastrointestinal Bleeding, Gastrointestinal Ulcer
European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB)
The aim of this study is to assess the current management strategies in a pan-European "real-life" setting to uncover the unmet need in this area: non-variceal gastrointestinal bleedings.
- Conditions
- Non-variceal Upper Gastrointestinal Bleeding, Gastrointestinal Ulcer, Gastrointestinal Hemorrhage
- Trial name
- ENERGIB (NCT00797641)
- Where
- 97 sites in Belgium, Greece and 5 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Gastric Ulcer, Duodenal Ulcer
Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer
The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00595517
- Testing
- Esomeprazole 20 mg
- Where
- 3 sites in Japan
- Volunteers
- 395 people
- Sponsor
- AstraZeneca
Stress Ulcers, Stress-related Mucosal Disease (SRMD)
China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients
Stress ulcers or stress-related mucosal disease (SRMD) is defined as "acute superficial inflammation lesions of the gastric mucosa induced when an individual is subject to abnormally elevated physiologic demands."[1] Studies have…
- Trial name
- SUP (NCT02316990)
- Where
- 11 sites in China
- Volunteers
- 1,416 people
- Sponsor
- AstraZeneca
Gastric Ulcer, Duodenal Ulcer
Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID
The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00542789
- Testing
- Esomeprazole
- Where
- 39 sites in Japan
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Reflux Esophagitis
The Efficacy of i-Scan for Detecting Reflux Esophagitis
Endoscopy is a widely used modality for the diagnosis and classification of Gastroesophageal reflux disease (GERD), and the extent of esophageal mucosal breaks on endoscopy can be assessed.
- Trial name
- NCT01381991
- Testing
- i-scan
- Where
- South Korea
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Konkuk University Hospital
Peptic Ulcer
The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers
An open-label, multiple-dose, single-arm, phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers
- Trial name
- NCT02581696
- Testing
- Lafutidine, Irsogladine maleate
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Gastroesophageal Reflux Disease, GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis
- Trial name
- NCT01397084
- Testing
- esomeprazole 20 mg
- Volunteers
- 107 people
- Sponsor
- AstraZeneca